Bavarian Nordic A/S
Bavarian Nordic Reports Successful Safety Data From Phase II Study With IMVAMUNE
Published in AIDS Weekly, November 17th, 2008
II study with IMVAMUNE(R) in HIV infected subjects that confirms the excellent safety profile of IMVAMUNE(R). Within the next few days the safety report of this study will be submitted to the FDA and this will trigger a USD
25 million milestone payment under the RFP-3 contract. The clinical safety report constitutes a major part of the data package that will be used to potentially support the use of IMVAMUNE(R) in a declared emergency.
In support of using IMVAMUNE(R) as a smallpox vaccine in individuals otherwise contraindicated to receive conventional...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2008-11-17)
More Articles from AIDS Weekly
- Massachusetts Institute of Technology
MIT captures single-cell response to vaccination - Rockefeller University Press
How HIV vaccine might have increased odds of infection - University of California - Los Angeles
Study finds fears of HIV transmission in families with infected parent - Wellcome Trust Sanger Institute
DNA chunks, chimps and humans - HIV/AIDS
Reports from Ruhr University highlight recent research in HIV/AIDS - HIV/AIDS
Research from K. Champenois and co-authors provides new data about HIV/AIDS - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
